Jefferies assumed coverage of Revolution Medicines (RVMD) with a Buy rating and a price target of $140, up from $88, calling it “the most exciting company in oncology today.” The RAS(ON) platform “looks game-changing,” daraxonrasib has “a real shot to redefine” second-line pancreatic cancer, and the firm’s work suggests the Phase 3 RASolute 302 study is likely to hit at its first interim, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Daraxonrasib Poised to Become Pancreatic Cancer Standard of Care on Strong RASolute 302 Outlook and Accelerated Launch Path
- Erasca price target raised to $20 from $10 at Stifel
- Revolution Medicines Doubles Down on Costly RAS Push
- Revolution Medicines put volume heavy and directionally bearish
- Revolution Medicines assumed with a Buy at UBS